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records of pharmacists at six Scottish cancer treatment centres
and units was undertaken where a standardised care plan (Mac-
intyre et al. Development of a system for reporting pharmaceu-
tical care issues in cancer patients receiving chemotherapy.
Pharm J 2003;271:266–7) was utilised. Records were entered
into an electronic version of the care plan and activities were
recorded according to deﬁnitions by McAnaw (McAnaw JJ.
Development of novel approaches to demonstrate the quality of
drug therapy use. PhD thesis. Glasgow: University of Strathclyde.
2003). Categorisation system for pharmaceutical care issues was
utilised and its reliability was assessed with Cohen’s Kappa.
RESULTS: A total of 2737 pharmaceutical care issues were
recorded from 729 patients receiving 3376 cycles of chemother-
apy (0.8 care issues per cycle), 2711 care issues were categorised
into Drug Therapy Problems (DTP’s) as deﬁned by Cipolle et al.
(Cipolle RJ et al. Identifying, resolving, and preventing drug
therapy problems: the pharmacist’s responsibility. In: Pharma-
ceutical Care Practice. New York: McGraw-Hill. 1998). Relia-
bility of the categorisation assessed with Cohen’s Kappa was
found to be at least “good” (Kappa between 0.60 and 0.75) in
all but one categories tested. The most common DTP addressed
was “adverse drug reaction” (77%). Others included “dose too
high/dose too low” (9%) and “additional medication needs”
(8%). Care issues were also categorised as “checks” (67%) or
“changes” (33%). Checks were mainly “veriﬁcations” prior to
administration (75%) rather than ongoing “monitoring” (25%).
Changes were “modiﬁcations” (49%), individualised “adjust-
ments” (38%) or “prompted revisions” of the treatment (13%).
CONCLUSIONS: Results show the system’s potential to
promote standardised documentation of pharmaceutical care
delivered to patients undergoing cancer chemotherapy as an
important contribution to quality assurance in cancer
chemotherapy.
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OBJECTIVES: Cancer is the second leading cause of death in the
United States and a major contributor to health care expendi-
tures. Our objective was to investigate whether disparities in 
outpatient treatment costs exist among an economically homoge-
nous group—those on Medicaid. METHODS: Utilizing Mary-
land Medicaid administrative claims data, a retrospective cohort
design was employed to examine disparities in ambulatory treat-
ment costs of breast, colorectal and prostate cancer treatments
by region, race and gender. We report mean and median results
by each demographic category and test for the statistical signif-
icance of each. Lorenz curves are plotted and Gini coefﬁcients
calculated for each type of cancer. RESULTS: We do not ﬁnd a
consistent trend in ambulatory costs across the 3 cancers by tra-
ditional demographic variables. Lorenz curves indicate highly
unequal distributions of costs. Gini coefﬁcients are 0.687 for
breast cancer, 0.757 for colorectal cancer, and 0.774 for prostate
cancer. CONCLUSIONS: Signiﬁcant variation in non-hospital
based expenditures exists for breast, colorectal and prostate
cancers in a population of homogeneous socio-economic status
and uniform insurance entitlement. Observed individual level
disparities are not consistent across cancers by region, race or
gender, but the majority of this low income population receives
very little ambulatory care.
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OBJECTIVES: To assess patient outcomes of various strategies
for determining diagnosis and resectability in patients with sus-
pected pancreatic cancer (PC). METHODS: We used data from
a prospective study of 193 patients with suspected PC performed
at the Charité University Hospital from August, 1999–Novem-
ber, 2000. These patients underwent each of the following six
different diagnostic procedures: ultrasound (US), magnetic reso-
nance imaging (MR), computed tomography (CT), endoscopic
ultrasound (EUS), ﬂuorodeoxyglucose positron emissiontomog-
raphy (PET), and endoscopic retrograde cholangiopancreaticog-
raphy (ERCP). We developed a decision tree to predict diagnostic
accuracy and resectability using the conditional probabilities
derived from our study. In the ﬁrst step, we sought to maximize
the number of patients having both diagnostic and resectability
state correctly classiﬁed. As the varying types of incorrect assess-
ments lead to different clinical consequences, we determined a
clinical consequence score to assess the impact of these conse-
quences on mortality and quality of life (e.g. inadequate treat-
ment following an imperfect classiﬁcation). This score ranged
from 100 (best scenario, benign diagnosed as benign) to 0 (worst
scenario, benign and unresectable classiﬁed as resectable). Each
possible scenario’s score was estimated by a clinical panel of
experts. In the second step, these score values were incorporated
into the decision tree as patient outcome weights. RESULTS:
Regarding correct classiﬁcation, best test performance was
achieved with MR alone, correctly classifying 79% of patients
as benign, malignant/resectable, or malignant/unresectable. The
combination of PET and EUS had the worst performance with
only 61% of patients correctly classiﬁed. The incorporation of
the clinical consequence score lead only to minor differences
between the strategies. Probabilistic sensitivity analysis showed
robust results in both portions of the study. CONCLUSIONS:
The incorporation of the clinical consequence score failed to
determine a superior strategy. Once quality-adjusted life years
and costs are estimated, we will perform a cost-effectiveness
analysis.
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OBJECTIVE: To use meta-analysis techniques to pool both clin-
ical effect and cost data to provide an absolute estimate of 
the likely survival and cost of BSC in advanced NSCLC.
METHODS: A systematic review of published clinical and eco-
nomic literature identiﬁed patient cohorts with stage IIIb and IV
NSCLC receiving BSC at any stage of treatment. Data on 12
month, 24 month and median survival, as well as cost of BSC,
were extracted from the original publications. With appropriate
ﬁxed and random effect meta-analysis techniques, data of com-
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parable studies were pooled to obtain summary measures of cost
and effect. Cost data were converted to US dollars and expressed
as year 2002 prices. RESULTS: In total, 53 studies were identi-
ﬁed and reviewed, of which 13 were analysed. Median survival
of BSC was estimated at 4.90 months (95% CI 4.46–5.35). The
12-month and 24-month survival proportions were 16% (95%
CI13–19) and 4% (95% CI 2–7) respectively. Survival was 
not affected by the stage at which BSC was given. Four papers 
from two countries were suitable for pooling total costs of BSC,
and resulted in an estimate of US $6519 (95% CI $5740–$7297)
per person. CONCLUSION: Absolute effects, as observed in
clinical trials, pooled with meta-analysis techniques can provide
key information for outcomes research, such as pharmacoeco-
nomic modeling studies. Here we provide pooled survival and
cost estimates for BSC. These can be used for economic evalua-
tions of recently developed drugs in stage IIIb and IV NSCLC
where an indirect comparison may need to be made with BSC.
Pooling cost data is problematic due to differing treatment pat-
terns and relative prices over years and across countries. Conse-
quently, caution should be taken when pooling costs and it is
advised to only pool costs if studies are comparable. Otherwise
ranges of costs as observed in the different studies should be
reported.
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OBJECTIVES: Pharmacoeconomic studies for terminal cancer
require preference-based rather than disease-speciﬁc measures of
QoL. Mapping enables evaluators to elicit information about
societal preferences where only disease-speciﬁc QoL data are
available. METHODS: Responses to HRQoL questions from a
phase-2 trial of VELCADE for relapsed and refractory multiple
myeloma patients (n = 202 in SUMMIT1 trial), were used to
derive utility scores from the original scales used in SUMMIT
and those from a generic QoL tool (EQ-5D). Questions relevant
to the EQ-5D were identiﬁed (EORTC-QLQC30, EORTC-
MY24, FACT-Fatigue and FACT/GOG-Ntx) and ﬁve summary
measures of severity (corresponding to the ﬁve EQ-5D dimen-
sions) obtained. The summary measures were transformed into
the corresponding EQ-5D scale for each dimension. EQ-5D
utility scores were validated using the answers to questions on
“Overall QoL” and “Overall Health” from EORTC-QLQC30
(Questions 29 & 30). RESULTS: Utility scores appear similar
across patient groups as deﬁned by serological response to
VELCADE, for an overall utility score of 0.65. Utility mapping
is sensitive to differences in overall QoL and overall health. This
ﬁnding is robust to the passage of time for overall QoL differ-
ences, but derived utility scores decline as time passes for a given
overall level of health. The utility scores are robust to mapping
algorithms that use summary measures (i.e. mean/median) to
aggregate reported severity levels for relevant questions within
each EQ-5D dimension but change markedly if the worst
reported level of severity for each dimension is used instead.
CONCLUSIONS: A method for deriving utility scores from
reported HRQoL outcomes is proposed that yields results con-
sistent with previous reports for MM patients. Using mapping
algorithms to derive utility scores from generic instruments in
situations where information on societal preferences for QoL
outcomes is not available is a feasible and sensitive option for
providing valid estimates of patient well-being for terminal 
conditions.
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OBJECTIVES: To conduct a meta-analysis on the diagnostic
accuracy of ﬁve screening tests for colorectal cancer (CRC): 
fecal occult blood test (FOBT), double-contrast barium 
enema (DCBE), ﬂexible sigmoidoscopy (FSIG), conventional
colonoscopy (COL) and computed tomography colonoscopy
(CTCOL). METHODS: A literature search was carried out in
MEDLINE for each test. Articles were reviewed by two inde-
pendent reviewers. Inclusion criteria were: 1) RCTs or observa-
tional studies of CRC screening; 2) patients with low/average
risk of CRC; 3) complete data to calculate sensitivity and speci-
ﬁcity. Exclusion criteria were: 1) non-peer reviewed articles; 2)
articles whose primary aim was not to assess CRC screening; 3)
articles not in English/French; 4) articles published prior to 1975;
and 5) high risk screening populations. Weighted linear regres-
sion was used to identify signiﬁcant covariates. Sensitivity and
speciﬁcity were pooled for relevant subgroups. RESULTS: The
initial literature search found 399 articles for FOBT, 253 for
DCBE, 394 for FSIG, 434 for COL, and 345 for CTCOL. Of
these, 12, 8, 10, 8, and 13 articles respectively, were included in
the ﬁnal analysis. With the exception of colonoscopy the remain-
ing tests showed evidence of heterogeneity and threshold effect.
Signiﬁcant covariates included study design and type of FOBT.
Pooled sensitivity and speciﬁcity (95% CI) for randomized FOBT
and FSIG trials were 0.738 (0.705,0.768), 0.960 (0.959,0.961),
0.822 (0.770,0.864), and 0.997 (0.994,0.998) respectively. For
the remaining tests, the pooled sensitivity and speciﬁcity (95%
CI) were 0.767 (0.728,0.802), 0.975 (0.970,0.979) for all DCBE
studies, 0.867 (0.828,0.898), 0.995 (0.991,0.998) for all COL
studies and 0.879 (0.840,0.910), 0.964 (0.956,0.971) for all
CTCOL studies. CONCLUSIONS: When heterogeneity is
present within test groups, results from pooled sensitivity and
speciﬁcity can be misleading. A planned future step is to estimate
diagnostic odds ratios and build summary ROC curves which
are more reliable estimates of test accuracy for evidence 
synthesis.
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OBJECTIVE: The aim of the project is to use Artiﬁcial Neural
Networks (ANNs)—representatives of computational intelli-
gence—for medical effect prediction, which could help in 
the extrapolation of pharmacoeconomics analysis’ results.
METHODS: To depict neural data analysis tools, a database
containing 100 non-small cell lung cancer (NSCLC) patients in
non-operative IIIB and IV stage has been used. Each patient was
described using 30 factors (i.e. sex, age, anticancer drugs dosage)
and, as an output value, the expected survival time was estab-
lished. The role of the ANN based system was to predict the
patient’s survival time based on the above mentioned informa-
tion. Binary values were tested as outcomes. Positive values
(coded as 1) meant that patient survival time would be equal to
or longer than 35 weeks. Negative values (coded as 0) meant
that the patient survival time would be shorter than 35 weeks.
